Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

389 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and Performance Outcomes of a Self-Expanding Transcatheter Aortic Heart Valve: The BIOVALVE Trials.
Schäfer U, Kempfert J, Verheye S, Maisano F, Thiele H, Landt M, Haude M, Rudolph TK, Ince H, Kische S, Treede H, Tonino P, Conradi L. Schäfer U, et al. Among authors: haude m. JACC Cardiovasc Interv. 2020 Jan 27;13(2):157-166. doi: 10.1016/j.jcin.2019.07.058. Epub 2019 Oct 16. JACC Cardiovasc Interv. 2020. PMID: 31629751 Free article. Clinical Trial.
Safety and clinical performance of a drug eluting absorbable metal scaffold in the treatment of subjects with de novo lesions in native coronary arteries: Pooled 12-month outcomes of BIOSOLVE-II and BIOSOLVE-III.
Haude M, Ince H, Kische S, Abizaid A, Tölg R, Alves Lemos P, Van Mieghem NM, Verheye S, von Birgelen C, Christiansen EH, Barbato E, Garcia-Garcia HM, Waksman R; BIOSOLVE-II and III investigators. Haude M, et al. Catheter Cardiovasc Interv. 2018 Dec 1;92(7):E502-E511. doi: 10.1002/ccd.27680. Epub 2018 Aug 5. Catheter Cardiovasc Interv. 2018. PMID: 30079472 Free PMC article. Clinical Trial.
Sustained Safety and Performance of the Second-Generation Sirolimus-Eluting Absorbable Metal Scaffold: Pooled Outcomes of the BIOSOLVE-II and -III Trials at 3 Years.
Haude M, Ince H, Kische S, Toelg R, Van Mieghem NM, Verheye S, von Birgelen C, Christiansen EH, Barbato E, Garcia-Garcia HM, Waksman R. Haude M, et al. Cardiovasc Revasc Med. 2020 Sep;21(9):1150-1154. doi: 10.1016/j.carrev.2020.04.006. Epub 2020 Apr 13. Cardiovasc Revasc Med. 2020. PMID: 32917533 Clinical Trial.
BIOSOLVE-IV-registry: Safety and performance of the Magmaris scaffold: 12-month outcomes of the first cohort of 1,075 patients.
Verheye S, Wlodarczak A, Montorsi P, Torzewski J, Bennett J, Haude M, Starmer G, Buck T, Wiemer M, Nuruddin AAB, Yan BP, Lee MK. Verheye S, et al. Among authors: haude m. Catheter Cardiovasc Interv. 2021 Jul 1;98(1):E1-E8. doi: 10.1002/ccd.29260. Epub 2020 Sep 3. Catheter Cardiovasc Interv. 2021. PMID: 32881396 Free PMC article.
The REMEDEE trial: a randomized comparison of a combination sirolimus-eluting endothelial progenitor cell capture stent with a paclitaxel-eluting stent.
Haude M, Lee SW, Worthley SG, Silber S, Verheye S, Erbs S, Rosli MA, Botelho R, Meredith I, Sim KH, Stella PR, Tan HC, Whitbourn R, Thambar S, Abizaid A, Koh TH, Den Heijer P, Parise H, Cristea E, Maehara A, Mehran R. Haude M, et al. JACC Cardiovasc Interv. 2013 Apr;6(4):334-43. doi: 10.1016/j.jcin.2012.10.018. Epub 2013 Mar 20. JACC Cardiovasc Interv. 2013. PMID: 23523459 Free article. Clinical Trial.
Sustained Safety and Performance of a Second-Generation Sirolimus-Eluting Absorbable Metal Scaffold: Long-Term Data of the BIOSOLVE-II First-in-Man Trial at 5 Years.
Haude M, Toelg R, Lemos PA, Christiansen EH, Abizaid A, von Birgelen C, Neumann FJ, Wijns W, Ince H, Kaiser C, Lim ST, Escaned J, Eeckhout E, Garcia-Garcia HM, Waksman R. Haude M, et al. Cardiovasc Revasc Med. 2022 May;38:106-110. doi: 10.1016/j.carrev.2021.07.017. Epub 2021 Jul 22. Cardiovasc Revasc Med. 2022. PMID: 34364807
389 results